AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00089219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFA
Description: vaccine adjuvant
Study NCT00089219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: melanoma helper peptides
Study NCT00089219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: vaccine adjuvant
Study NCT01100424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opti-Free RepleniSH
Description: Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
Study NCT01100424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReNu MultiPlus
Description: Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
Study NCT01100424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balafilcon A
Description: Commercially available silicone hydrogel contact lenses removed from blister pack and soaked overnight in Opti-Free Replenish, ReNu MultiPlus, or Unisol 4, then applied to the eye and worn for 2 hours.
Study NCT01100424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unisol 4
Description: Commercially available non preserved sterile saline solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
Study NCT04274205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: Brief supportive psychotherapy
Study NCT01571388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib
Description: Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
Study NCT02711462 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-06687234
Description: PF-06687234 will be administered via the SC or the IV route and in either single dose or multiple doses
Study NCT02711462 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: In Cohorts 1 and 2, up to 1 subject will receive placebo. In all other Cohorts (Cohorts 3 to 11), up to 2 subjects will receive placebo.
Study NCT02522117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
Study NCT02522117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
Study NCT04712292 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical procedure for confirmed or suspected colorectal cancer
Description: Surgical procedure for cancer may include:~* any radical surgery (right or left hemicolectomy, rectal resection, abdomino-perineal resection, total colectomy, proctocolectomy, and others depending on the tumor site and other tumor characteristics),~* surgery for radicalization of cancer polyps previously removed endoscopically~* surgery for excision of large polyps which are not removable endoscopically~* staging surgery (laparoscopy or laparotomy), in case of advanced-non operable cancer~* palliative surgery (defined as any surgery with no curative intent)
Study NCT01529606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Composite restoration and tooth cleaning
Description: Standard preventive treatment will be repeated on semi-annual (6-month) recall visits. All composite restorations will be placed according to the manufacturer's instruction.
Study NCT01529606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma treatment
Description: plasma treatment after preparation and for caries prevention
Study NCT03795415 — intervention group
Intervention type: BEHAVIORAL
Intervention: Gundo So
Description: Gundo-So was adapted from a program established in quebec. It has been implemented in Mali following 3 phases: 1) cultural adaptation; 2) validation using a pre-post intervention evaluation; 3) scale-up~The programm consists on 9 group meetings group spread over 9 weeks (for 8 WLHIV + 2 trained community-based leaders). Each meeting has some particular thematics with adapted tools.
Study NCT02572453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV
Study NCT01341496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epigenetically Modified Autologous Tumor
Description: 5x 10\^7 autologous tumor cells emulsified in 0.5 mL ISCOMATRIX adjuvant will be administered IM every 4 weeks for 6 months
Study NCT01341496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each 4 week treatment cycle
Study NCT01341496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each 4 week vaccine cycle.
Study NCT02219256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 solution
Study NCT02219256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to TAK-079
Description: Placebo to TAK-079 solution
Study NCT04621721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait/balance & resistive exercise
Description: Walking forward and back, walking with head motion, static standing, Standing Partial Tandem, Tandem Standing heel to toe, Standing with head turns Single leg stance and March in place. Resistance exercises include: calf raises, lunges, supine leg curls and extensions.
Study NCT04621721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait/balance & resistive exercise
Description: Walking forward and back, walking with head motion, static standing, Standing Partial Tandem, Tandem Standing heel to toe, Standing with head turns Single leg stance and March in place. Resistance exercises include: calf raises, lunges, supine leg curls and extensions.
Study NCT03778008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant bovine basic fibroblast growth factor
Description: Recombinant bovine basic fibroblast growth factor is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of recombinant bovine basic fibroblast growth factor at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade > 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
Study NCT03778008 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition
Description: Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade > 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
Study NCT01787552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Study NCT01787552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC424
Study NCT04703413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric® OrigoTM and LoFric® SenseTM
Description: The investigational device is either a CE-marked LoFric® OrigoTM , 40 cm, CH12/CH14 or LoFric® SenseTM, 15 cm, CH12. They are all intermittent urinary catheters with a Nelaton tip from a more sustainable manufacturing process. All subjects will use the investigational device for 30 days each.
Study NCT02667652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: short biliarypancreatic limb
Description: biliarypancreatic limb:50cm;roux limb:150cm.
Study NCT02667652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long biliarypancreatic limb
Description: biliarypancreatic limb:100cm;roux limb:100cm.
Study NCT02443623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with ACAM2000
Description: In this study (VA-008), healthy adult male and female volunteers who meet the requirements for source plasma donors and study entry criteria will be vaccinated with the ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacture of VIGIV. There are possible risks associated with ACAM2000 vaccination. To ensure the safety of plasma donors, risk factor screening procedures and the collection of post-vaccination safety data will be assessed throughout the study.
Study NCT01427140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyunsaturated fatty acid group
Description: Addition of polyunsaturated fatty acids to the diet in the form of pastries
Study NCT01427140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saturated fatty acid group
Description: Addition of saturated fatty acids to the diet in the form of pastries
Study NCT03222908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention1: Contract Agreement
Description: Smoking Cessation Contract
Study NCT03222908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention2: Implementation Intentions
Description: Smoking Cessation Contract with worksheet for implementation intentions
Study NCT00853294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule
Description: Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose fasting
Study NCT00853294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension
Description: Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose fasting
Study NCT04076241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: The investigators applied six different OMT techniques including rib raising, diaphragm release, suboccipital decompression, first rib mobilization, mediastinum mobilization and thoracic inlet myofascial release. Rib raising is used to increase the mobility of the rib cage and to reduce vasoconstriction by regulating sympathetic tone. Diaphragm release is used to increase diaphragm movement. Suboccipital decompression involves traction of the base of the skull. We aim to improve respiration with mobilization of the first rib which is associated with sternum, sympathetic truncus and important vascular structures. Thoracic inlet is an important structure resisting intrathoracic pressure changes during respiration. Finally, the goal of the mediastinum mobilization is to increase the mobility of the rib cage by providing relaxation in the tension of the facial tissues.
Study NCT04076241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic manipulative treatment
Description: The investigators applied six different OMT techniques including rib raising, diaphragm release, suboccipital decompression, first rib mobilization, mediastinum mobilization and thoracic inlet myofascial release. Rib raising is used to increase the mobility of the rib cage and to reduce vasoconstriction by regulating sympathetic tone. Diaphragm release is used to increase diaphragm movement. Suboccipital decompression involves traction of the base of the skull. We aim to improve respiration with mobilization of the first rib which is associated with sternum, sympathetic truncus and important vascular structures. Thoracic inlet is an important structure resisting intrathoracic pressure changes during respiration. Finally, the goal of the mediastinum mobilization is to increase the mobility of the rib cage by providing relaxation in the tension of the facial tissues.
Study NCT04076241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga respiratory training
Description: Nadishodhana pranayama (Alternate nostril breathing), Ujjayi pranayama (Psychic breath) and Bhramari pranayama (Humming bee breath) were used for the study. Nadishodhana is one of the most common yoga breathing exercises and involves breathing through one nostril while closing the other one. The patients performed 2 sets of 8 breathing cycles with a resting time of 2 minutes between the sets. Ujjayi Pranayama involves soft contraction of laryngeal muscles and the partial closure of the glottis. The patients performed 2 sets of 10 breathing cycles per session with an inspiration:expiration phase as 1:2. Bhramari Pranayama includes a nasal humming sound during exhalation to create slight vibrations on the laryngeal walls, and the inner walls of the nostrils. The patients applied 2 sets of 10 breathing cycles per session with a respiration rate of 3-4/min.
Study NCT03504917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: Participants will receive 10 mg of oral administration balovaptan once a day (QD).
Study NCT03504917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo.
Study NCT00321763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate Influenza Vaccine GSK1247446A - 3 different formulations
Description: Single dose, Intramuscular injection
Study NCT00321763 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix TM
Description: Single dose, Intramuscular injection
Study NCT03519009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPS Plus Abstinence-Contingent Wage Supplement
Description: Participants are offered abstinence-contingent wage supplements if they obtain and maintain competitive employment. The wage supplements are designed to promote employment while reinforcing drug abstinence. To help participants obtain and maintain competitive employment, participants will receive Individual Placement and Support (IPS) supported employment. IPS is a supported employment intervention that has been proven effective in promoting employment in adults with severe mental illness. To promote employment and prevent relapse to drug use, participants will receive IPS Plus Abstinence-Contingent Wage Supplements.
Study NCT00968461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenethyl Isothiocyanate (PEITC)
Description: Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
Study NCT03332615 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Clinicians in the intervention arm will be taught Motivational Interviewing via a coaching model in which a didactic session is followed by feedback through review of clinicians' audio-recorded encounters.
Study NCT03332615 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait-list control
Description: After consent, clinicians in the wait-list control arm will complete a survey to self-assess their motivational interviewing skills and burnout.
Study NCT05475145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resin based sealing [RBS]
Study NCT02495389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Mirabegron is a medication for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved by the United States Food and Drug Administration (FDA) in July 2012.
Study NCT03377439 — intervention group
Intervention type: OTHER
Intervention: Platelet function tests
Description: Platelet reactivity was measured by flow cytometry, filopodia detection and the platelet aggregation analyzer.
Study NCT02380924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSP loaded RBC using EryDex System
Description: Intravenous infusion of 10 mg DSP encapsulated in autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
Study NCT02380924 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham treated RBC using the EryDex System
Description: Intravenous infusion of sham treated autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
Study NCT02124811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Study NCT00414908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase delayed release capsule
Description: 24,000 unit capsule
Study NCT00414908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo
Study NCT00124787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate
Description: Dimenhydrinate PO q 6 hours x 4 doses
Study NCT00124787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PO q 6 hours x 4 doses
Study NCT04330001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon Fluid Accommodating Intraocular Lens
Description: Intraocular lens intended to treat presbyopia by dynamically adjusting power, resulting in a continuous range of vision from distance to near.
Study NCT04330001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Top Con Autorefractor
Description: Device intended to automatically determine the focusing characteristics of the eye
Study NCT01800682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramodol Extended-Release (ER)
Description: Tramodol ER, will be administered orally as either 25, 50 or 100 milligram tablet, once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
Study NCT03691675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug coated balloon
Description: Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy
Study NCT00225017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: atazanavir 400 mg once daily
Study NCT00225017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: current antiretroviral regimen
Description: Continue current antiretroviral regimen for 24 weeks, single or RTV-boosted PI plus > 2 NRTIs
Study NCT04422327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic capsule
Description: Each probiotic capsule contains 5 x 10\^8 CFU B. longum 35624® and 5 x 10\^8 CFU B. longum 1714™ with corn starch and magnesium stearate.~The probiotic capsule will be supplied by PrecisionBiotics Ltd.
Study NCT01125631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 8.5 mg/kg
Description: 8.5 mg/kg every 8 weeks (4 doses total)
Study NCT02266485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBB 515 BS
Study NCT02266485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Study NCT02266485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02715908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBEC0101
Description: Etanercept 50mg
Study NCT03273062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolcapone 200 MG
Description: Tolcapone 200 MG TID
Study NCT03273062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolcapone 200 MG
Description: Tolcapone 200 MG TID
Study NCT03273062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
Study NCT03273062 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
Study NCT03735615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sprint interval training
Description: Each training session will be performed 3 times per week for 3 weeks. Each session consists of 3-5x20 sec all-out cycling efforts against a load corresponding to 0.05-0.07 kg/kg body mass, separated by 3-5 min of low intensity cycling (20-50 W), on a lode bicycle ergometer (Excalibur Sport V2.0, Groningen, the Netherlands). All training sessions includes a 5 min warm-up and 3 min cool-down.
Study NCT00826839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill and microdose lupron
Description: Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)
Study NCT00826839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2 patch/antagonist
Description: Estradiol transdermal system 0.1 mg/day (25 cm2 patch. Patch changed every other day x 3. Final patch left on for about 7 days. Total duration of therapy approximately 14 days.~Gonadotropin-releasing hormone antagonist 0.25 mg subcutaneously every other day for 3 total doses.
Study NCT01597986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: oral